keyword
https://read.qxmd.com/read/38683419/the-effect-of-antihyperglycemic-medications-on-covid-19-a-meta-analysis-and-systematic-review-from-observational-studies
#1
JOURNAL ARTICLE
Zhi-Hui Song, Qiao-Ming Huang, Shan-Shan Xu, Jian-Bo Zhou, Chao Zhang
BACKGROUND: Diabetes, a chronic disease worldwide, may be associated with a poorer prognosis in patients with coronavirus disease 2019 (COVID-19). While some antihyperglycemic medications may be beneficial, others may increase the risk of adverse clinical outcomes of COVID-19. We aimed to analyze the effect of antihyperglycemic medications on COVID-19. METHODS: We searched the Web of Science, Cochrane Library, EMBASE, PubMed, and Scopus databases from December 2019 to June 2022 to identify literature related to patients with COVID-19 and type 2 diabetes mellitus (T2DM) treated with antihyperglycemic medications...
April 29, 2024: Therapeutic Innovation & Regulatory Science
https://read.qxmd.com/read/38680683/hormone-based-pharmacotherapy-for-metabolic-dysfunction-associated-fatty-liver-disease
#2
JOURNAL ARTICLE
Zara Siu Wa Chui, Yaqian Xue, Aimin Xu
Metabolic dysfunction-associated fatty liver disease (MAFLD) has reached epidemic proportions globally in parallel to the rising prevalence of obesity. Despite its significant burden, there is no approved pharmacotherapy specifically tailored for this disease. Many potential drug candidates for MAFLD have encountered setbacks in clinical trials, due to safety concerns or/and insufficient therapeutic efficacy. Nonetheless, several investigational drugs that mimic the actions of endogenous metabolic hormones, including thyroid hormone receptor β (THRβ) agonists, fibroblast growth factor 21 (FGF21) analogues, and glucagon-like peptide-1 receptor agonists (GLP-1RAs), showed promising therapeutic efficacy and excellent safety profiles...
April 2024: Med Rev (2021)
https://read.qxmd.com/read/38680477/health-technology-assessment-evaluation-of-7-glucagon-like-peptide-1-receptor-agonists-for-the-treatment-of-type-2-diabetes-mellitus
#3
REVIEW
Zeyu Xie, Jia Hu, Mengting Li, Xiao Hu, Jisheng Chen
PURPOSE: This study provides a reference for healthcare organizations in the selection and rational use of glucagon-like peptide-1 receptor agonists (GLP-1RAs), based on the Rapid Guide for Drug Evaluation and Selection in Chinese Medical Institutions (Second Edition). METHODS: According to the Rapid Guide for Drug Evaluation and Selection in Chinese Medical Institutions (Second Edition) released in 2023, relevant databases such as PubMed, Cochrane, and Embase, drug labels, and clinical guidelines were searched for drug information...
2024: Risk Management and Healthcare Policy
https://read.qxmd.com/read/38679221/long-term-efficacy-and-safety-of-once-weekly-semaglutide-for-weight-loss-in-patients-without-diabetes-a-systematic-review-and-meta-analysis-of-randomized-controlled-trials
#4
JOURNAL ARTICLE
Areesha Moiz, Jeremy Y Levett, Kristian B Filion, Katya Peri, Pauline Reynier, Mark J Eisenberg
Semaglutide, a glucagon-like peptide-1 receptor agonist, has demonstrated clinically important weight loss effects in patients with type 2 diabetes. However, its effects on sustained weight loss among individuals without diabetes remains unclear. Our objective was to examine the long-term efficacy and safety of semaglutide use for weight loss among individuals with overweight/obesity and without diabetes. MEDLINE, Embase, and the Cochrane Libraries were systematically searched to identify randomized controlled trials (RCTs) that randomized participants with overweight/obesity but without diabetes to once-weekly 2...
April 26, 2024: American Journal of Cardiology
https://read.qxmd.com/read/38678094/effectiveness-of-dialbetesplus-a-self-management-support-system-for-diabetic-kidney-disease-randomized-controlled-trial
#5
JOURNAL ARTICLE
Kayo Waki, Mitsuhiko Nara, Syunpei Enomoto, Makiko Mieno, Eiichiro Kanda, Akiko Sankoda, Yuki Kawai, Kana Miyake, Hiromichi Wakui, Yuya Tsurutani, Nobuhito Hirawa, Tadashi Yamakawa, Shiro Komiya, Akihiro Isogawa, Shinobu Satoh, Taichi Minami, Tamio Iwamoto, Tatsuro Takano, Yasuo Terauchi, Kouichi Tamura, Toshimasa Yamauchi, Masaomi Nangaku, Naoki Kashihara, Kazuhiko Ohe
We evaluated the effectiveness of a mobile health (mHealth) intervention for diabetic kidney disease patients by conducting a 12-month randomized controlled trial among 126 type 2 diabetes mellitus patients with moderately increased albuminuria (urinary albumin-to-creatinine ratio (UACR): 30-299 mg/g creatinine) recruited from eight clinical sites in Japan. Using a Theory of Planned Behavior (TPB) behavior change theory framework, the intervention provides patients detailed information in order to improve patient control over exercise and dietary behaviors...
April 27, 2024: NPJ Digital Medicine
https://read.qxmd.com/read/38677478/higher-expression-of-mir-15b-5p-with-inclusion-of-fresh-lean-beef-as-part-of-a-healthy-dietary-pattern-is-inversely-associated-with-markers-of-cardio-metabolic-disease-risk
#6
JOURNAL ARTICLE
Kamille A Piacquadio, Lee M Margolis, Jess A Gwin, Heather J Leidy
BACKGROUND: Considerable controversy exists surrounding the consumption of red meat and its impacts on cardio-metabolic health and may further impact risk factors at the molecular level. OBJECTIVE: The purpose of this study was to examine the acute effects of dietary patterns, varying in red meat quantity, on the expression of circulating microRNA (miRNA)s, which are emerging biomarkers of metabolic dysfunction and chronic disease severity. METHODS: Secondary analyses were performed from plasma samples collected within a randomized, crossover design study in 16 women with overweight (mean ± SD, age = 33 ± 9...
April 25, 2024: Journal of Nutrition
https://read.qxmd.com/read/38677445/glucagon-like-peptide-1-class-drugs-show-clear-protective-effects-in-parkinson-s-and-alzheimer-s-disease-clinical-trials-a-revolution-in-the-making
#7
REVIEW
Christian Hölscher
Parkinson's disease (PD) is a complex syndrome for which there is no disease-modifying treatment on the market. However, a group of drugs from the Glucagon-like peptide-1 (GLP-1) class have shown impressive improvements in clinical phase II trials. Exendin-4 (Bydureon), Liraglutide (Victoza, Saxenda) and Lixisenatide (Adlyxin), drugs that are on the market as treatments for diabetes, have shown clear effects in improving motor activity in patients with PD in phase II clinical trials. In addition, Liraglutide has shown improvement in cognition and brain shrinkage in a phase II trial in patients with Alzheimer disease (AD)...
April 25, 2024: Neuropharmacology
https://read.qxmd.com/read/38676552/glucagon-like-receptor-1-agonists-and-stroke-a-systematic-review-and-meta-analysis-of-cardiovascular-outcome-trials
#8
REVIEW
Anastasia Adamou, Fotios Barkas, Haralampos J Milionis, George Ntaios
BACKGROUND: In stroke survivors, approximately 15% and 60% exhibit concurrent diabetes mellitus and overweight/obesity, respectively, necessitating heightened secondary prevention efforts. Despite Glucagon-like receptor-1 agonists (GLP-1 RAs) demonstrating improved outcomes for those with diabetes mellitus or obesity, their underutilization persists among eligible individuals. This systematic review and meta-analysis investigated the impact of GLP-1 RAs on stroke risk. The findings aim to optimize the implementation of this therapeutic strategy in stroke survivors with diabetes mellitus or obesity...
April 27, 2024: International Journal of Stroke: Official Journal of the International Stroke Society
https://read.qxmd.com/read/38676506/phloridzin-s-diabetic-wound-healing-potential-through-dpp-4-enzyme-inhibition-a-review-article
#9
JOURNAL ARTICLE
Khushi Sharma, Vadivelan Ramachandran, Ashutosh Sharma, Tharani Mohanasundaram, Harshini Mageshkumar
Diabetic wound healing is a dynamic medical process that takes place in an environment within the body that is complex and contains elevated sugar levels, oxygen deprivation, and cellular oxidative stress. Phloridzin (Phlorizin) is one of the most well-known polyphenols found in apples because of its anti-inflammatory, antioxidant, antibacterial, antidiabetic, and antiseptic properties; it can also play a significant part in the healing of diabetic wounds. The study aimed to investigate the role of phloridzin as an efficient DPP-4 inhibitor with additional therapeutic effects in diabetic wound healing, as Dipeptidyl Peptidase-4 (DPP-4) expression increases in response to increases in glucose, Reactive Oxygen Species (ROS), and inflammation...
April 26, 2024: Current Diabetes Reviews
https://read.qxmd.com/read/38675498/development-of-syringaldehyde-as-an-agonist-of-the-glp-1-receptor-to-alleviate-diabetic-disorders-in-animal-models
#10
JOURNAL ARTICLE
Jenpei Lee, Yingxiao Li, Juei-Tang Cheng, I-Min Liu, Kai-Chun Cheng
The phenolic aldehyde syringaldehyde (SA) has been shown to have an antihyperglycemic effect in diabetic rats due to increased glucose utilization and insulin sensitivity. To understand the direct effect of SA on the GLP-1 receptor, STZ-induced diabetic rats were used. The levels of pro-inflammatory cytokines, liver enzymes, and renal function were measured using specific ELISA kits. The mechanisms of SA effects were investigated using CHO-K1 cells, pancreatic Min-6 cells, and cardiomyocyte H9c2 cells. The results indicated that the antihyperglycemic effect of SA in diabetic rats was abolished by blocking the GLP-1 receptor with an antagonist...
April 22, 2024: Pharmaceuticals
https://read.qxmd.com/read/38675485/effect-of-glp-1-receptor-agonist-on-ischemia-reperfusion-injury-in-rats-with-metabolic-syndrome
#11
JOURNAL ARTICLE
Marko Ravic, Ivan Srejovic, Jovana Novakovic, Marijana Andjic, Jasmina Sretenovic, Maja Muric, Marina Nikolic, Sergey Bolevich, Kirill Alekseevich Kasabov, Vladimir Petrovich Fisenko, Aleksandra Stojanovic, Vladimir Jakovljevic
Metabolic syndrome (MetS) represents an important factor that increases the risk of myocardial infarction, and more severe complications. Glucagon Like Peptide-1 Receptor Agonists (GLP-1RAs) exhibit cardioprotective potential, but their efficacy in MetS-related myocardial dysfunction has not been fully explored. Therefore, we aimed to assess the effects of exenatide and dulaglutide on heart function and redox balance in MetS-induced rats. Twenty-four Wistar albino rats with induced MetS were divided into three groups: MetS, exenatide-treated (5 µg/kg), dulaglutide-treated (0...
April 19, 2024: Pharmaceuticals
https://read.qxmd.com/read/38674919/effects-of-wheat-biscuits-enriched-with-plant-proteins-incorporated-into-an-energy-restricted-dietary-plan-on-postprandial-metabolic-responses-of-women-with-overweight-obesity
#12
RANDOMIZED CONTROLLED TRIAL
Maria-Christina Kanata, Amalia E Yanni, Chrysi Koliaki, Irene Pateras, Ioanna A Anastasiou, Alexander Kokkinos, Vaios T Karathanos
This study investigates the effect of daily consumption of wheat biscuits enriched with plant proteins in postprandial metabolic responses of women with overweight/obesity who follow an energy-restricted diet. Thirty apparently healthy women participated in a 12-week randomized controlled trial and were assigned either to a control (CB) or an intervention (PB) group. Participants consumed daily either a conventional (CB) or an isocaloric wheat biscuit enriched with plant proteins (PB) containing high amounts of amino acids with appetite-regulating properties, i...
April 20, 2024: Nutrients
https://read.qxmd.com/read/38674708/age-dependent-differences-in-postprandial-bile-acid-metabolism-and-the-role-of-the-gut-microbiome
#13
JOURNAL ARTICLE
Soumia Majait, Emma C E Meessen, Mark Davids, Youssef Chahid, Steven W Olde Damink, Frank G Schaap, Ellis Marleen Kemper, Max Nieuwdorp, Maarten R Soeters
Ageing changes the impact of nutrition, whereby inflammation has been suggested to play a role in age-related disabilities such as diabetes and cardiovascular disease. The aim of this study was to investigate differences in postprandial bile-acid response and its effect on energy metabolism between young and elderly people. Nine young, healthy men and nine elderly, healthy men underwent a liquid mixed-meal test. Postprandial bile-acid levels, insulin, glucose, GLP-1, C4, FGF19 and lipids were measured. Appetite, body composition, energy expenditure and gut microbiome were also measured...
April 10, 2024: Microorganisms
https://read.qxmd.com/read/38674415/association-between-the-glp1r-a316t-mutation-and-adolescent-idiopathic-scoliosis-in-french-canadian-and-italian-cohorts
#14
JOURNAL ARTICLE
Émilie Normand, Anita Franco, Stefan Parent, Giovanni Lombardi, Marco Brayda-Bruno, Alessandra Colombini, Alain Moreau, Valérie Marcil
Studies have revealed anthropometric discrepancies in girls with adolescent idiopathic scoliosis (AIS) compared to non-scoliotic subjects, such as a higher stature, lower weight, and lower body mass index. While the causes are still unknown, it was proposed that metabolic hormones could play a role in AIS pathophysiology. Our objectives were to evaluate the association of GLP1R A316T polymorphism in AIS susceptibility and to study its relationship with disease severity and progression. We performed a retrospective case-control association study with controls and AIS patients from an Italian and French Canadian cohort...
April 11, 2024: Genes
https://read.qxmd.com/read/38673991/new-mechanisms-to-prevent-heart-failure-with-preserved-ejection-fraction-using-glucagon-like-peptide-1-receptor-agonism-glp-1-ra-in-metabolic-syndrome-and-in-type-2-diabetes-a-review
#15
REVIEW
Jorge E Jalil, Luigi Gabrielli, María Paz Ocaranza, Paul MacNab, Rodrigo Fernández, Bruno Grassi, Paulina Jofré, Hugo Verdejo, Monica Acevedo, Samuel Cordova, Luis Sanhueza, Douglas Greig
This review examines the impact of obesity on the pathophysiology of heart failure with preserved ejection fraction (HFpEF) and focuses on novel mechanisms for HFpEF prevention using a glucagon-like peptide-1 receptor agonism (GLP-1 RA). Obesity can lead to HFpEF through various mechanisms, including low-grade systemic inflammation, adipocyte dysfunction, accumulation of visceral adipose tissue, and increased pericardial/epicardial adipose tissue (contributing to an increase in myocardial fat content and interstitial fibrosis)...
April 17, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38673931/assessment-of-thyroid-carcinogenic-risk-and-safety-profile-of-glp1-ra-semaglutide-ozempic-therapy-for-diabetes-mellitus-and-obesity-a-systematic-literature-review
#16
REVIEW
Catalin Vladut Ionut Feier, Razvan Constantin Vonica, Alaviana Monique Faur, Diana Raluca Streinu, Calin Muntean
The broadening application of glucagon-like peptide (GLP)-1 receptor agonists, specifically semaglutide (Ozempic) for the management of diabetes and obesity brings a critical need to evaluate its safety profile, considering estimates of up to 20 million prescriptions per year in the US until 2035. This systematic review aims to assess the incidence of thyroid cancer and detail the spectrum of adverse events associated with semaglutide, focusing on its implications for patient care. Through a systematic search of PubMed, Scopus, and Embase databases up to December 2023, ten randomized controlled trials (RCTs) involving 14,550 participants, with 7830 receiving semaglutide, were analyzed, with an additional number of 18 studies that were separately discussed because they reported data from the same RCTs...
April 15, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38673503/potential-therapeutic-targets-in-obesity-sleep-apnea-diabetes-and-fatty-liver-disease
#17
REVIEW
Christina Gu, Nicole Bernstein, Nikita Mittal, Soumya Kurnool, Hannah Schwartz, Rohit Loomba, Atul Malhotra
Obesity and metabolic syndrome affect the majority of the US population. Patients with obesity are at increased risk of developing type 2 diabetes (T2DM), obstructive sleep apnea (OSA), and metabolic dysfunction-associated steatotic liver disease (MASLD), each of which carry the risk of further complications if left untreated and lead to adverse outcomes. The rising prevalence of obesity and its comorbidities has led to increased mortality, decreased quality of life, and rising healthcare expenditures. This phenomenon has resulted in the intensive investigation of exciting therapies for obesity over the past decade, including more treatments that are still in the pipeline...
April 12, 2024: Journal of Clinical Medicine
https://read.qxmd.com/read/38673469/assessment-of-cardiovascular-risk-categories-and-achievement-of-therapeutic-targets-in-european-patients-with-type-2-diabetes
#18
JOURNAL ARTICLE
Delia Reurean-Pintilei, Claudia-Gabriela Potcovaru, Teodor Salmen, Liliana Mititelu-Tartau, Delia Cinteză, Sandra Lazăr, Anca Pantea Stoian, Romulus Timar, Bogdan Timar
Background: Individuals diagnosed with type 2 diabetes mellitus (T2DM) are more prone to experiencing severe cardiovascular (CV) events, often occurring at a younger age, due to a complex interplay of risk factors. T2DM diagnosis inherently classifies patients as belonging to a higher CV risk group. In light of the increased susceptibility to severe CV outcomes, our study aims to assess the distribution of CV risk categories and the attainment of therapeutic targets among Romanian patients diagnosed with T2DM...
April 10, 2024: Journal of Clinical Medicine
https://read.qxmd.com/read/38672620/from-diabetes-to-oncology-glucagon-like-peptide-1-glp-1-receptor-agonist-s-dual-role-in-prostate-cancer
#19
REVIEW
Abdulrahman Alhajahjeh, Raad Al-Faouri, Hisham F Bahmad, Taima' Bader, Ryan W Dobbs, Ahmed A Abdulelah, Wassim Abou-Kheir, Elai Davicioni, David I Lee, Mohammed Shahait
Glucagon-like peptide-1 (GLP-1), an incretin hormone renowned for its role in post-meal blood sugar regulation and glucose-dependent insulin secretion, has gained attention as a novel treatment for diabetes through GLP-1 receptor agonists (GLP-1-RA). Despite their efficacy, concerns have been raised regarding the potential associations between GLP-1-RA and certain malignancies, including medullary thyroid cancer. However, evidence of its association with prostate cancer (PCa) remains inconclusive. This review delves into the intricate relationship between GLP-1-RA and PCa, exploring the mechanisms through which GLP-1-Rs may impact PCa cells...
April 18, 2024: Cancers
https://read.qxmd.com/read/38672181/nafld-in-the-21st-century-current-knowledge-regarding-its-pathogenesis-diagnosis-and-therapeutics
#20
REVIEW
Dimitris Kounatidis, Natalia G Vallianou, Eleni Geladari, Maria Paraskevi Panoilia, Anna Daskou, Theodora Stratigou, Irene Karampela, Dimitrios Tsilingiris, Maria Dalamaga
Non-alcoholic fatty liver disease (NAFLD) is a major public health issue worldwide. It is the most common liver disease in Western countries, andits global prevalence is estimated to be up to 35%. However, its diagnosis may be elusive, because liver biopsy is relatively rarely performed and usually only in advanced stages of the disease. Therefore, several non-invasive scores may be applied to more easily diagnose and monitor NAFLD. In this review, we discuss the various biomarkers and imaging scores that could be useful in diagnosing and managing NAFLD...
April 9, 2024: Biomedicines
keyword
keyword
3122
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.